Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Aug;54(2):749.
doi: 10.1002/hep.24310. Epub 2011 Jun 27.

Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved

Harel Dahari, Jeremie Guedj, Alan S Perelson
Comment

Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved

Harel Dahari et al. Hepatology. 2011 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors disclose no conflicts.

Figures

Figure 1
Figure 1
Representative serum HCV RNA decline from baseline during the first week of treatment with silibinin monotherapy (red squares), RG7128 1500-mg BID (blue circles; manuscript in preparation), daily 10MIU IFN (black triangles) and telaprevir+PegIFN (gray triangles). Solid lines were used to emphasize plausible phases of viral decline.
See this image and copyright information in PMC

Comment on

  • Multiple effects of silymarin on the hepatitis C virus lifecycle.
    Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, Pécheur EI, Graf TN, Oberlies NH, Lohmann V, Cao F, Tavis JE, Polyak SJ. Wagoner J, et al. Hepatology. 2010 Jun;51(6):1912-21. doi: 10.1002/hep.23587. Hepatology. 2010. PMID: 20512985 Free PMC article.

References

    1. Wagoner J, Negash A, Kane OJ, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology. 2010 Jun;51(6):1912–1921. - PMC - PubMed
    1. Wagoner J, Morishima C, Graf TN, et al. Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation. PLoS One. 2011;6(1):e16464. - PMC - PubMed
    1. Ahmed-Belkacem A, Ahnou N, Barbotte L, et al. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology. 2010 Mar;138(3):1112–1122. - PubMed
    1. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008 Nov;135(5):1561–1567. - PubMed
    1. Biermer M, Berg T. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin. Gastroenterology. 2009 Jul;137(1):390–391. - PubMed